Citius Pharmaceuticals (OTC: CTXR) is a specialty pharmaceutical company that develops and commercializes therapeutic products. The company’s product portfolio includes: Suprenza ODT, a phentermine orally disintegrating tablet used for the treatment of obesity; and Hydrocortisone-Lidocaine Cream, in phase 2 of clinical trials for the treatment of hemorrhoids. Citius has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products throughout North America. The company recently announced its acquisition of Leonard Meron, a late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration on anti-infective drugs. For more information, visit the company’s website at www.citiuspharma.com